More than 50 cancer organizations to issue a call to action urging individuals, providers, and insurers to increase access to and utilization of low-dose CT scans for those at high risk for lung cancer.
Tagrisso (osimertinib) plus chemotherapy delivers a statistically significant and clinically meaningful survival benefit compared to Tagrisso monotherapy in the first-line treatment of patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, according to results from the final overall survival analysis of the FLAURA2 phase III trial.
